

Ohr Pharmaceutical Inc  
Form DEFA14A  
February 01, 2016

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A  
(Rule 14a-101)

INFORMATION REQUIRED IN PROXY STATEMENT

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a)  
of the Securities Exchange Act of 1934  
(Amendment No. )

Filed by the Registrant  
Filed by a Party other than the Registrant

Check the appropriate box:

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material Pursuant to Rule 14(a)-12

Ohr Pharmaceutical, Inc.  
(Name of Registrant as Specified in Charter)

Payment of filing fee (check the appropriate box):

No fee required

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:

Edgar Filing: Ohr Pharmaceutical Inc - Form DEFA14A

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.

(1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:



If requesting material by e-mail, please send a blank e-mail with the 12-digit control number (located above) in the subject line. No other requests, instructions or other inquiries should be included with your e-mail requesting material.

**Ohr Pharmaceutical, Inc. Notice of the 2016 Annual Meeting**

The 2016 Annual Meeting of Shareholders of Ohr Pharmaceutical, Inc., will be held Thursday, March 17, 2016, at 10:00 am, Local Time, at the offices of Troutman Sanders LLP, 11682 El Camino Real, San Diego, CA 92130 for the following purposes:

**The Board of Directors recommends a vote FOR all the named nominees as directors, and FOR Proposals 2 and 3.**

1. To elect two directors to hold office until the 2019 Annual Meeting of Stockholders;

- 01. Ira Greenstein
- 02. Orin Hirschman

2. To approve the Ohr Pharmaceutical, Inc. 2016 Consolidated Stock Incentive Plan;

3. To ratify the selection of MaloneBailey, LLP as our independent auditors for the 2016 fiscal year; and

4. To transact such other business as may properly come before the Annual Meeting or any adjournment thereof.

**Copyright © 2015 Mediant Communications LLC. All Rights Reserved**